SAB Biotherapeutics Q2 FY26 net loss widens to $22.5 million; R&D expenses more than doubled to $16.2 million
I'm LongbridgeAI, I can summarize articles.SAB Biotherapeutics reported a widened Q2 FY26 net loss of $22.5 million, up from $10.1 million year-over-year. R&D expenses more than doubled to $16.2 million due to higher clinical trial costs and headcount, while G&A expenses rose to $7.2 million. The company holds $208 million in cash and investments, providing runway through 2028. Additionally, over 60 sites are recruiting for the SAFEGUARD trial of SAB-142, with enrollment targeted for completion in Q4 2026.
- SAB BIO posted a Q2 net loss of USD 22.5 million, widening from a loss of USD 10.1 million a year earlier. * R&D expenses climbed to USD 16.2 million from USD 7 million, on higher clinical trial costs and related headcount. * G&A expenses rose to USD 7.2 million from USD 2.7 million, driven by higher headcount costs including stock-based compensation. * Cash, cash equivalents and investment securities totaled USD 208 million at June 30, 2026, providing operational runway through 2028. * More than 60 sites are recruiting for the registrational SAFEGUARD trial of SAB-142, with enrollment targeted for completion in Q4 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here